Donna Bernstein
Overview
Explore the profile of Donna Bernstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raygada M, John L, Liu A, Schultz J, Thomas B, Bernstein D, et al.
J Cancer Res Clin Oncol
. 2024 May;
150(5):227.
PMID: 38700789
Introduction: Chordoma is a rare slow-growing tumor that occurs along the length of the spinal axis and arises from primitive notochordal remnants (Stepanek et al., Am J Med Genet 75:335-336,...
2.
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy
Kaczanowska S, Murty T, Alimadadi A, Contreras C, Duault C, Subrahmanyam P, et al.
Cancer Cell
. 2023 Dec;
42(1):35-51.e8.
PMID: 38134936
Chimeric antigen receptor T cells (CAR-Ts) have remarkable efficacy in liquid tumors, but limited responses in solid tumors. We conducted a Phase I trial (NCT02107963) of GD2 CAR-Ts (GD2-CAR.OX40.28.z.iC9), demonstrating...
3.
Akshintala S, Sundby R, Bernstein D, Glod J, Kaplan R, Yohe M, et al.
Clin Cancer Res
. 2023 Jul;
29(17):3329-3339.
PMID: 37398992
Purpose: Antibodies against insulin-like growth factor (IGF) type 1 receptor have shown meaningful but transient tumor responses in patients with rhabdomyosarcoma (RMS). The SRC family member YES has been shown...
4.
Wedekind M, Reilly K, Del Rivero J, Lockridge R, Allen T, Raygada M, et al.
Pediatr Blood Cancer
. 2023 Jun;
:e30495.
PMID: 37345354
Rare tumors across the world are lacking adequate knowledge, resources, and community. Through partnership with patients, advocacy organizations, researchers, and clinicians, we have developed a comprehensive, longitudinal, prospective, and retrospective...
5.
DAngelo S, Melchiori L, Merchant M, Bernstein D, Glod J, Kaplan R, et al.
Cancer Discov
. 2018 Jun;
8(8):944-957.
PMID: 29891538
We evaluated the safety and activity of autologous T cells expressing NY-ESO-1, an affinity-enhanced T-cell receptor (TCR) recognizing an HLA-A2-restricted NY-ESO-1/LAGE1a-derived peptide, in patients with metastatic synovial sarcoma (NY-ESO-1T cells)....
6.
Shah N, Merchant M, Cole D, Jayaprakash N, Bernstein D, Delbrook C, et al.
Pediatr Blood Cancer
. 2016 Feb;
63(6):997-1005.
PMID: 26891067
Background: Vincristine sulfate liposome injection (VSLI; Marqibo®) is an encapsulated preparation of standard vincristine in sphingomyelin/cholesterol liposomes. Clinical trials in adults have demonstrated safety, tolerability, and activity, leading to Food...
7.
Merchant M, Bernstein D, Amoako M, Baird K, Fleisher T, Morre M, et al.
Clin Cancer Res
. 2016 Jan;
22(13):3182-91.
PMID: 26823601
Purpose: Patients with metastatic or relapsed pediatric sarcomas receive cytotoxic regimens that induce high remission rates associated with profound lymphocyte depletion, but ultimately few survive long term. We administered adjuvant...
8.
Merchant M, Wright M, Baird K, Wexler L, Rodriguez-Galindo C, Bernstein D, et al.
Clin Cancer Res
. 2015 Nov;
22(6):1364-70.
PMID: 26534966
Purpose: Ipilimumab is a first-in-class immune checkpoint inhibitor approved for treatment of metastatic melanoma but not studied in children until this phase I protocol. Experimental Design: This study examined safety,...
9.
Fox E, Widemann B, Hawkins D, Jayaprakash N, Dagher R, Aikin A, et al.
Clin Cancer Res
. 2009 Nov;
15(23):7361-7.
PMID: 19920107
Purpose: To compare the effectiveness, tolerance, and pharmacokinetics of a single dose of pegfilgrastim to daily filgrastim in children and young adults with sarcomas treated with dose-intensive combination chemotherapy. Experimental...
10.
Mackall C, Rhee E, Read E, Khuu H, Leitman S, Bernstein D, et al.
Clin Cancer Res
. 2008 Aug;
14(15):4850-8.
PMID: 18676758
Purpose: Patients with metastatic or recurrent Ewing's sarcoma family of tumors and alveolar rhabdomyosarcoma have <25% 5-year survival in most studies. This study administered a novel immunotherapy regimen aimed at...